89 related articles for article (PubMed ID: 8378080)
1. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours.
Kovar H; Auinger A; Jug G; Aryee D; Zoubek A; Salzer-Kuntschik M; Gadner H
Oncogene; 1993 Oct; 8(10):2683-90. PubMed ID: 8378080
[TBL] [Abstract][Full Text] [Related]
2. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.
Komuro H; Hayashi Y; Kawamura M; Hayashi K; Kaneko Y; Kamoshita S; Hanada R; Yamamoto K; Hongo T; Yamada M
Cancer Res; 1993 Nov; 53(21):5284-8. PubMed ID: 8221663
[TBL] [Abstract][Full Text] [Related]
3. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
4. Sites and types of p53 mutations in an unselected series of colorectal cancers in The Netherlands.
Van Den Broek MH; Renault B; Fodde R; Verspaget H; Griffioen G; Khan PM
Anticancer Res; 1993; 13(3):587-92. PubMed ID: 8317886
[TBL] [Abstract][Full Text] [Related]
5. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy.
Ganly I; Soutar DS; Brown R; Kaye SB
Br J Cancer; 2000 Jan; 82(2):392-8. PubMed ID: 10646894
[TBL] [Abstract][Full Text] [Related]
6. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation.
Tanaka S; Toh Y; Adachi E; Matsumata T; Mori R; Sugimachi K
Cancer Res; 1993 Jun; 53(12):2884-7. PubMed ID: 8389246
[TBL] [Abstract][Full Text] [Related]
7. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.
Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA
Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
9. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog.
Van Leeuwen IS; Hellmèn E; Cornelisse CJ; Van den Burgh B; Rutteman GR
Anticancer Res; 1996; 16(6B):3737-44. PubMed ID: 9042250
[TBL] [Abstract][Full Text] [Related]
10. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
11. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
[TBL] [Abstract][Full Text] [Related]
12. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
[TBL] [Abstract][Full Text] [Related]
13. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
14. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas.
Huang Y; Meltzer SJ; Yin J; Tong Y; Chang EH; Srivastava S; McDaniel T; Boynton RF; Zou ZQ
Cancer Res; 1993 Apr; 53(8):1889-94. PubMed ID: 8467510
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations selected in vivo when mouse mammary epithelial cells form hyperplastic outgrowths are not necessary for establishment of mammary cell lines in vitro.
Ozbun MA; Jerry DJ; Kittrell FS; Medina D; Butel JS
Cancer Res; 1993 Apr; 53(7):1646-52. PubMed ID: 8453637
[TBL] [Abstract][Full Text] [Related]
16. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
17. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings.
Eeles RA; Warren W; Knee G; Bartek J; Averill D; Stratton MR; Blake PR; Tait DM; Lane DP; Easton DF
Oncogene; 1993 May; 8(5):1269-76. PubMed ID: 8479749
[TBL] [Abstract][Full Text] [Related]
18. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
[TBL] [Abstract][Full Text] [Related]
19. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
20. Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations.
McKenzie KE; Siva A; Maier S; Runnebaum IB; Seshadri R; Sukumar S
Clin Cancer Res; 1997 Sep; 3(9):1669-73. PubMed ID: 9815858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
